S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC

D Ferry,K J O'Byrne,R Shah,M Kumar,G Skailes,M Hill,P Leonard,S Pirrie,M Nicolson,D Dunlop,P Leonard,B Crosse,P Woll,A Chetiyawardana,H W Jarrett,P Wells,L J Billingham,C Lewanski,J Thompson

doi:10.1136/thoraxjnl-2011-201054b.85

S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC

D Ferry, K J O'Byrne + Show 17 more

Open Access

https://doi.org/10.1136/thoraxjnl-2011-201054b.85

Copy DOI

Journal: Thorax	Publication Date: Dec 1, 2011
Citations: 10

Affiliation: New Cross Hospital, Whittington Hospital, Royal Derby Hospital, Royal Preston Hospital, University College London, University of Birmingham, Aberdeen Royal Infirmary, Beatson West of Scotland Cancer Centre, Huddersfield Royal Infirmary, University of Sheffield, Walsall Manor Hospital, Whipps Cross University Hospital, Imperial College Healthcare NHS Trust, Heartlands Hospital

#Optimal Dose Of Cisplatin #Carboplatin AUC + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundPlatins are considered key drugs in treating advanced NSCLC. Carboplatin has been reported as inferior to cisplatin in meta-analyses while the optimal dose of cisplatin is unclear.MethodsEligibility was by histologically...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Thorax

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.